[go: up one dir, main page]

WO2025155215A1 - Additif bio-actif - Google Patents

Additif bio-actif

Info

Publication number
WO2025155215A1
WO2025155215A1 PCT/RU2024/000016 RU2024000016W WO2025155215A1 WO 2025155215 A1 WO2025155215 A1 WO 2025155215A1 RU 2024000016 W RU2024000016 W RU 2024000016W WO 2025155215 A1 WO2025155215 A1 WO 2025155215A1
Authority
WO
WIPO (PCT)
Prior art keywords
magnesium
vitamin
glucose
normalization
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/RU2024/000016
Other languages
English (en)
Russian (ru)
Inventor
Владимир Евгеньевич ПОПОВ
Владислав Викторович МАТВЕЕВ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obshchestvo S Ogranichennoy Otvetstvennostyu "splat Global"
Original Assignee
Obshchestvo S Ogranichennoy Otvetstvennostyu "splat Global"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obshchestvo S Ogranichennoy Otvetstvennostyu "splat Global" filed Critical Obshchestvo S Ogranichennoy Otvetstvennostyu "splat Global"
Priority to PCT/RU2024/000016 priority Critical patent/WO2025155215A1/fr
Publication of WO2025155215A1 publication Critical patent/WO2025155215A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • Document US20220079201A1 discloses the creation of a vitamin and mineral composition for pregnant women, which includes, among other things, vitamins B1, B6 and magnesium.
  • Magnesium can be included in the composition in one of the selected forms, such as: acetate, citrate, gluconate, stearate, chloride and others.
  • the composition can be used to restore the nutritional deficiency observed in patients during physiologically stressful conditions, which, in certain embodiments of the invention, include prenatal, pregnant and lactating women.
  • One of the solutions is to provide a composition according to the present invention, consisting of magnesium citrate, magnesium bisglycinate, vitamin B6 and vitamin B1.
  • the invention relates to a biologically active supplement in the form of a capsule containing as active substances a combination consisting of magnesium bisglycinate - 45-50 mg, magnesium citrate - 590-600 mg, vitamin B1 - 2-3 mg, vitamin B6 - 2-3 mg, and containing lecithin and gum arabic as auxiliary substances.
  • Magnesium bisglycinate is a special form of magnesium supplement in which a magnesium atom is bonded to two molecules of the amino acid glycine. This chelated form of magnesium is highly bioavailable, meaning it is easily absorbed by the body. Chemically, magnesium bisglycinate has the formula HeMgNzC ⁇ . It is a white powder that is soluble in water. It is a stable compound that does not break down easily under normal conditions. Magnesium bisglycinate is often preferred as a supplement over other forms of magnesium due to its improved absorption and reduced gastrointestinal side effects. Because it is chelated with glycine, it bypasses the typical digestive process, reducing the likelihood of digestive discomfort or diarrhea, which can be a common side effect of other magnesium supplements. Additionally, magnesium bisglycinate is considered well-tolerated and safe for most people when taken at recommended dosages. It has no known drug interactions and may be helpful for people with magnesium deficiency, muscle spasms, migraines, or those who need extra magnesium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un additif bio-actif sous forme d'une capsule contenant en qualité de substances actives une combinaison comprenant 45-50 mg de bisglycinate de magnésium, 590-900 mg de citrate de magnésium, 2-3 mg de vitamine B1, 2-3 mg de vitamine B6, et contenant en qualité de substances auxiliaires de la lécithine et de la gomme arabique.
PCT/RU2024/000016 2024-01-19 2024-01-19 Additif bio-actif Pending WO2025155215A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/RU2024/000016 WO2025155215A1 (fr) 2024-01-19 2024-01-19 Additif bio-actif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2024/000016 WO2025155215A1 (fr) 2024-01-19 2024-01-19 Additif bio-actif

Publications (1)

Publication Number Publication Date
WO2025155215A1 true WO2025155215A1 (fr) 2025-07-24

Family

ID=96471856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2024/000016 Pending WO2025155215A1 (fr) 2024-01-19 2024-01-19 Additif bio-actif

Country Status (1)

Country Link
WO (1) WO2025155215A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
EP2915433A1 (fr) * 2014-03-04 2015-09-09 Lifewave, Inc. Composition nutritionelle pour l'énergie
FR3078628B1 (fr) * 2018-03-09 2020-03-27 Id Phar Composition comestible sous forme de gelule pour la prevention de troubles de l’humeur
US11318150B1 (en) * 2016-02-26 2022-05-03 Michelle Ann Toothman Vitamin supplement compositions with enhanced bioavailability
JP2022110470A (ja) * 2021-01-18 2022-07-29 敦 松永 体重増加抑制用食品組成物、サプリメント及び体重増加抑制剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
EP2915433A1 (fr) * 2014-03-04 2015-09-09 Lifewave, Inc. Composition nutritionelle pour l'énergie
US11318150B1 (en) * 2016-02-26 2022-05-03 Michelle Ann Toothman Vitamin supplement compositions with enhanced bioavailability
FR3078628B1 (fr) * 2018-03-09 2020-03-27 Id Phar Composition comestible sous forme de gelule pour la prevention de troubles de l’humeur
JP2022110470A (ja) * 2021-01-18 2022-07-29 敦 松永 体重増加抑制用食品組成物、サプリメント及び体重増加抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PELCZYńSKA MARTA, MOSZAK MAłGORZATA, BOGDAńSKI PAWEł: "The Role of Magnesium in the Pathogenesis of Metabolic Disorders", NUTRIENTS, M D P I AG, CH, vol. 14, no. 9, CH , pages 1714, XP093338797, ISSN: 2072-6643, DOI: 10.3390/nu14091714 *

Similar Documents

Publication Publication Date Title
Chaudhary et al. Implications of magnesium deficiency in type 2 diabetes: a review
Naderi et al. Timing, optimal dose and intake duration of dietary supplements with evidence-based use in sports nutrition
Greenhaff Creatine and its application as an ergogenic aid
Urbach Skin diseases nutrition and metabolism
US5629023A (en) Medical food composition for metabolic detoxification
JP5798648B2 (ja) アミノ酸組成物を含有する疲労防止剤
CN102935231A (zh) 使用瓜氨酸的治疗
EP3173089B1 (fr) Agent d'amélioration de fonction cérébrale et agent pour la prévention du déficit cognitif
CN107708683A (zh) 氨基酸补充
EP3977868A1 (fr) Complément alimentaire hautement énergétique à base de sucres inversés et de produits ergogènes à utiliser lors d'activités physiques, et son procédé de production
KR100481379B1 (ko) 체지방률을낮추고체조성을개선시키는식품조성물및체지방률을낮추고체조성을개선시키는방법
JP2004521127A (ja) 異常脂血症及び食事誘発性食後高血糖症のクロム／ビオチン療法
Soriano-Pérez et al. Magnesium and type 2 diabetes mellitus: clinical and molecular mechanisms
AU2016311131B2 (en) Mineral compositions for stimulating the carbohydrate metabolism
PT1235835E (pt) Complexos de histidina de crómio como suplementos nutricionais
EP1108429A2 (fr) Composition améliorée d'acides aminés pour fournir un complément d'acides aminés ou de protéines,notamment pour le traitement et/ou la gestion de certaines maladies
Van Loon et al. Dietary protein to support muscle hypertrophy
WO2025155215A1 (fr) Additif bio-actif
JPH01500030A (ja) 低カロリ−状態での窒素保持のための成長ホルモンの使用
US20120122984A1 (en) Methods of Treating Lipomas and Liposarcomas
Shiojima et al. Efficacy and safety of a novel dietary pyrroloquinoline quinone disodium salt on muscle strength and physical function in healthy volunteers: A randomized, double-blind, placebo-controlled study
WO2009008773A2 (fr) Mélange nutritionnel sec pour alimentation diététique (variantes)
Cammalleri et al. Egg white injury
KR100198159B1 (ko) 체중 감량을 위한 조성물
RU2849632C1 (ru) Смесь белковая восстанавливающая

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24919081

Country of ref document: EP

Kind code of ref document: A1